191 related articles for article (PubMed ID: 25262986)
1. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
[TBL] [Abstract][Full Text] [Related]
2. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.
Cortes U; Guilloteau K; Rouvreau M; Archaimbault C; Villalva C; Karayan-Tapon L
Exp Mol Pathol; 2015 Oct; 99(2):207-11. PubMed ID: 26163758
[TBL] [Abstract][Full Text] [Related]
3. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
4. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
[TBL] [Abstract][Full Text] [Related]
7. Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer.
Iida T; Mizuno Y; Kaizaki Y
Clin Chim Acta; 2019 Feb; 489():164-168. PubMed ID: 29111094
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC; Abrahamsen TW; Ekstrøm PO
Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
[TBL] [Abstract][Full Text] [Related]
9. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
10. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
[TBL] [Abstract][Full Text] [Related]
11. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.
Magnin S; Viel E; Baraquin A; Valmary-Degano S; Kantelip B; Pretet JL; Mougin C; Bigand M; Girardo B; Borg C; Ferrand C
J Mol Diagn; 2011 Sep; 13(5):485-92. PubMed ID: 21742054
[TBL] [Abstract][Full Text] [Related]
12. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
13. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Simi L; Pratesi N; Vignoli M; Sestini R; Cianchi F; Valanzano R; Nobili S; Mini E; Pazzagli M; Orlando C
Am J Clin Pathol; 2008 Aug; 130(2):247-53. PubMed ID: 18628094
[TBL] [Abstract][Full Text] [Related]
14. KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.
Jakubauskas A; Griskevicius L
Arch Pathol Lab Med; 2010 Apr; 134(4):620-4. PubMed ID: 20367313
[TBL] [Abstract][Full Text] [Related]
15. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
[TBL] [Abstract][Full Text] [Related]
16. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Ates O; Yalcin S
Indian J Cancer; 2019; 56(2):176-179. PubMed ID: 31062740
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
[TBL] [Abstract][Full Text] [Related]
18. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
19. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
[TBL] [Abstract][Full Text] [Related]
20. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
